Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Affiliations

• ¹ Eisai Inc., Woodcliff Lake, NJ, USA.
• ² Eisai Ltd., Hatfield, UK.
• ³ BioArctic AB, Warfvinges väg 35, SE-112 51, Stockholm, Sweden.
• ⁴ Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
• ⁵ Berry Consultants, LLC, Austin, TX, USA.
• ⁶ Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA. jcummings@cnsinnovations.com.